Chimerix Chooses Merck As HIV Partner, Keeps Broad-Spectrum Antiviral
This article was originally published in The Pink Sheet Daily
Executive Summary
The North Carolina-based start-up strikes a global deal for a Phase I HIV drug, which will allow it to fund late-stage trials on another lipid-antiviral conjugate.